The companies Clairity, Myriad Genetics, and MagView have joined forces to enhance the assessment of breast cancer risk by utilizing a combination of artificial intelligence and genetic data. This collaboration focuses on addressing a significant void in evaluating risks for women while minimizing any extra administrative tasks. By integrating Clairity’s sophisticated AI risk assessment technologies with Myriad’s genetic testing proficiency, this partnership strives to offer a more thorough and effective method for evaluating breast cancer risk.
Clairity, Myriad Genetics, and MagView Collaborate to Enhance Breast Cancer Risk Assessment Tool
